Abbvie Endocrine Inc Drug Patent Portfolio

Abbvie Endocrine Inc owns 2 orange book drugs protected by 11 US patents Given below is the list of Abbvie Endocrine Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8921326 Sustained-release composition and method for producing the same 05 Feb, 2031
Active
US9617303 Sustained-release composition and method for producing the same 22 Mar, 2028
Active
US8815801 Controlled release composition and method of producing the same 28 Jun, 2022 Expired
US6036976 Sustained release microspheres and preparation thereof 13 Dec, 2016 Expired
US7429559 Controlled release composition and method of producing the same 13 Dec, 2016 Expired
US5631020 Method for producing microcapsule 20 May, 2014 Expired
US5631021 Method for producing microcapsule 20 May, 2014 Expired
US5575987 Method of producing sustained-release microcapsules 02 Sep, 2013 Expired
US5716640 Method of producing sustained-release microcapsules 02 Sep, 2013 Expired
US5480656 Prolonged release microcapsules 02 Jan, 2013 Expired
US5643607 Prolonged release microcapsules 02 Jan, 2013 Expired


Given below is the list of recent legal activities going on the following drug patents of Abbvie Endocrine Inc.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 19 May, 2022 US8921326
Payment of Maintenance Fee, 8th Year, Large Entity 19 May, 2022 US8921326
Payment of Maintenance Fee, 8th Year, Large Entity 20 Jan, 2022 US8815801
Expire Patent 02 Nov, 2020 US7429559
Payment of Maintenance Fee, 4th Year, Large Entity 29 Sep, 2020 US9617303
Maintenance Fee Reminder Mailed 18 May, 2020 US7429559
Post Issue Communication - Certificate of Correction 10 Sep, 2018 US9617303
Payment of Maintenance Fee, 4th Year, Large Entity 14 Jun, 2018 US8921326
Payment of Maintenance Fee, 4th Year, Large Entity 14 Jun, 2018 US8921326
Payment of Maintenance Fee, 4th Year, Large Entity 15 Feb, 2018 US8815801
Mail O.P. Petition Decision 13 Jun, 2017 US9617303
Mail-Record a Petition Decision of Granted for Patent Term Adjustment after Issue 12 Jun, 2017 US9617303
O.P. Petition Decision 09 Jun, 2017 US9617303
Adjustment of PTA Calculation by PTO 09 Jun, 2017 US9617303
Record a Petition Decision of Granted for Patent Term Adjustment after Issue 09 Jun, 2017 US9617303


Abbvie Endocrine Inc Drug Patents' Oppositions Filed in EPO

Abbvie Endocrine Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 18, 2006, by Astellas B.V. Et Al.. This opposition was filed on patent number EP02738838A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP07859925A Dec, 2020 Instone Terry/ Read Howard Graham/Appleyard Lees IP LLP Granted and Under Opposition
EP02738838A Feb, 2007 QLT USA, Inc. Patent maintained as amended
EP02738838A May, 2006 MediGene Aktiengesellschaft Patent maintained as amended
EP02738838A May, 2006 Astellas B.V. et al. Patent maintained as amended


Abbvie Endocrine Inc's Family Patents

Abbvie Endocrine Inc drugs have patent protection in a total of 41 countries. It's US patent count contributes only to 10.8% of its total global patent coverage. 19 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Abbvie Endocrine Inc Drug List

Given below is the complete list of Abbvie Endocrine Inc's drugs and the patents protecting them.


1. Lupron Depot

Lupron Depot is protected by 10 patents, out of which 9 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8921326 Sustained-release composition and method for producing the same 05 Feb, 2031
(6 years from now)
Active
US8815801 Controlled release composition and method of producing the same 28 Jun, 2022
(2 years ago)
Expired
US6036976 Sustained release microspheres and preparation thereof 13 Dec, 2016
(7 years ago)
Expired
US7429559 Controlled release composition and method of producing the same 13 Dec, 2016
(7 years ago)
Expired
US5631020 Method for producing microcapsule 20 May, 2014
(10 years ago)
Expired
US5631021 Method for producing microcapsule 20 May, 2014
(10 years ago)
Expired
US5575987 Method of producing sustained-release microcapsules 02 Sep, 2013
(11 years ago)
Expired
US5716640 Method of producing sustained-release microcapsules 02 Sep, 2013
(11 years ago)
Expired
US5480656 Prolonged release microcapsules 02 Jan, 2013
(11 years ago)
Expired
US5643607 Prolonged release microcapsules 02 Jan, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lupron Depot's drug page


2. Lupron Depot-ped Kit

Lupron Depot-ped Kit is protected by 9 patents, out of which 7 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8921326 Sustained-release composition and method for producing the same 05 Feb, 2031
(6 years from now)
Active
US9617303 Sustained-release composition and method for producing the same 22 Mar, 2028
(3 years from now)
Active
US6036976 Sustained release microspheres and preparation thereof 13 Dec, 2016
(7 years ago)
Expired
US5631020 Method for producing microcapsule 20 May, 2014
(10 years ago)
Expired
US6036976 Sustained release microspheres and preparation thereof 13 Dec, 2013
(10 years ago)
Expired
US5575987 Method of producing sustained-release microcapsules 02 Sep, 2013
(11 years ago)
Expired
US5716640 Method of producing sustained-release microcapsules 02 Sep, 2013
(11 years ago)
Expired
US5480656 Prolonged release microcapsules 02 Jan, 2013
(11 years ago)
Expired
US5643607 Prolonged release microcapsules 02 Jan, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lupron Depot-ped Kit's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List